Ifinatamab Deruxtecan clinical trials
Ifinatamab Deruxtecan is named as an intervention in 17 current clinical trials in our USA, Spain, South Korea, China, Germany, Italy, Japan, Taiwan, France, Poland, Turkey, Israel, Netherlands, Brazil, Australia, Czechia, UK, Switzerland, Norway, Belgium, Ireland, Sweden, Denmark, Canada, Austria, Mexico, Singapore and Portugal registers. 13 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Merck Sharp & Dohme LLC (10). The most-studied condition is Small Cell Lung Cancer. The EU clinical trials register (CTIS) separately lists 2 authorised or ongoing trials.
How Ifinatamab Deruxtecan works
All drug targets →- Esophageal squamous cell carcinomaPhase 3
- Prostate cancerPhase 3
- Small cell lung carcinomaPhase 3
- Non-small cell lung carcinomaPhase 2
- Biliary tract cancerPhase 1/2
- Breast cancerPhase 1/2
- CancerPhase 1/2
- Cervical cancerPhase 1/2
- Colorectal cancerPhase 1/2
- Cutaneous melanomaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5095331, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13850, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Ifinatamab Deruxtecan
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Ifinatamab Deruxtecan
17 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Ifinatamab Deruxtecan in the EU trials register (CTIS)
2 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Ifinatamab Deruxtecan. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
2025-522339-32-00 · CTIS ↗ · Neoplasms
|
Phase 1 | Ongoing | Merck Sharp & Dohme LLC | France, Spain, Sweden + 8 more |
|
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F
2026-525213-31-00 · CTIS ↗ · Neoplasms
|
Phase 2 | Ongoing | Merck Sharp & Dohme LLC | Czechia, Germany, France + 1 more |
Conditions studied with Ifinatamab Deruxtecan
18 conditionsAll 18 conditions
| Condition (as registered) | Trials |
|---|---|
| Small Cell Lung Cancer | 2 |
| Esophageal Squamous Cell Carcinoma | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Prostate Cancer | 1 |
| Prostatic Neoplasms | 1 |
| Recurrent or Metastatic Solid Tumors | 1 |
| Castration-Resistant Prostatic Cancer | 1 |
| Metastasis | 1 |
| Advanced Solid Tumor | 1 |
| Malignant Solid Tumor | 1 |
| Extensive Stage-small Cell Lung Cancer | 1 |
| Extensive-stage Small-cell Lung Cancer | 1 |
| Malignant Neoplasm | 1 |
| Small-Cell Lung Cancer | 1 |
| Neuroendocrine Carcinoma | 1 |
| Small Cell Lung Cancer Extensive Stage | 1 |
| Lung Neoplasm | 1 |
| Oesophageal Squamous Cell Carcinoma | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Merck Sharp & Dohme LLC | 10 |
| Daiichi Sankyo | 6 |
| Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Ifinatamab Deruxtecan trials
How many clinical trials are testing Ifinatamab Deruxtecan?
17 current trials in our USA, Spain, South Korea, China, Germany, Italy, Japan, Taiwan, France, Poland, Turkey, Israel, Netherlands, Brazil, Australia, Czechia, UK, Switzerland, Norway, Belgium, Ireland, Sweden, Denmark, Canada, Austria, Mexico, Singapore and Portugal registers name Ifinatamab Deruxtecan (also registered as MK-2400) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Ifinatamab Deruxtecan trials recruiting patients?
Yes. 13 of the 17 trials are recruiting: 13 with sites in USA, 11 with sites in Spain, 10 with sites in South Korea, 9 with sites in China, 8 with sites in Germany, 9 with sites in Italy, 8 with sites in Japan, 9 with sites in Taiwan, 8 with sites in France, 8 with sites in Poland, 8 with sites in Turkey, 7 with sites in Israel, 6 with sites in Netherlands, 6 with sites in Brazil, 6 with sites in Australia, 5 with sites in Czechia, 4 with sites in UK, 4 with sites in Switzerland, 4 with sites in Norway, 4 with sites in Belgium, 3 with sites in Ireland, 3 with sites in Sweden, 3 with sites in Denmark, 3 with sites in Canada, 2 with sites in Austria, 2 with sites in Mexico, 2 with sites in Singapore and 2 with sites in Portugal. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Ifinatamab Deruxtecan clinical trials?
Merck Sharp & Dohme LLC (10), Daiichi Sankyo (6) and Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1). The number in brackets is how many trials each organisation leads.
Are there Ifinatamab Deruxtecan clinical trials in Ireland?
Yes. 3 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ifinatamab Deruxtecan works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ifinatamab Deruxtecan works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ifinatamab Deruxtecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.